StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Citi Reiterates $90 PT on Bristol-Myers Squibb Co. (BMY), 'We expect some FTC scrutiny...but given the Pfizer/ Arena outcome, we remain hopeful'
June 3, 2022 11:39 AM
Citi analyst Andrew Baum reiterated a Buy rating and $90.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY)/The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Next Articles
Bristol Myers Squibb's Turning Point Offer Fair, Says Stifel
June 3, 2022 12:07 PM
UPDATE: Raymond James Downgrades Bristol-Myers Squibb Co. (BMY) to Market Perform
June 3, 2022 10:41 AM
Pre-Open Stock Movers 06/03: Turning Point Doubles on Takeover; Tesla Falls as Musk Worried About Economy, Cutting 10% of Staff
June 3, 2022 9:10 AM
Bristol Myers boosts cancer drug portfolio with $4.1 billion Turning Point deal
June 3, 2022 7:06 AM
Bristol-Myers Squibb (BMY) to Acquire Turning Point Therapeutics (TPTX) for $76 Per Share
June 3, 2022 6:59 AM
Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
June 3, 2022 6:59 AM
Bristol-Myers Squibb (BMY) Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19
June 2, 2022 11:02 AM
Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19
June 2, 2022 11:01 AM
Immatics (IMTX) and Bristol Myers Squibb (BMY) Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
June 2, 2022 6:59 AM
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
June 2, 2022 6:59 AM
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
June 2, 2022 6:59 AM
Bristol-Myers Squibb (BMY) Announces Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus
June 1, 2022 6:59 AM
Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus
June 1, 2022 6:59 AM
